#USA #Chicago #EVERSANA #Precigen #PAPZIMEOS

EVERSANA and the U.S. Launch of PAPZIMEOS

On September 11, 2025, EVERSANA, a notable provider of global commercialization services within the life sciences sector, has been officially selected by Precigen, Inc. to spearhead the commercialization of PAPZIMEOS™, a groundbreaking therapy that recently received approval from the U.S. Food and Drug Administration (FDA) on August 14, 2025. This marks a significant advancement in the treatment of rare diseases, an area often fraught with challenges in bringing therapies to market.

What Is PAPZIMEOS?

PAPZIMEOS, scientifically referred to as zopapogene imadenovec-drba, represents a new frontier in therapeutic interventions for conditions that have historically been under-addressed in the pharmaceutical landscape. The approval by the FDA is a testament to the rigorous research and development efforts that have gone into the formulation of this therapy. With EVERSANA at the helm of its commercialization, there is optimism for broader patient access across the United States.

Strategic Partnership with Precigen

The collaboration between EVERSANA and Precigen commenced in late 2024, with a focus on streamlining the commercialization process for PAPZIMEOS. This partnership allows Precigen to utilize EVERSANA's comprehensive commercialization operations, which span pre-approval strategies as well as immediate post-approval launch services. Notably, the areas encompassed within this collaboration include crucial components such as market access, field deployment, medical affairs, and targeted marketing services – all essential for ensuring that that therapy reaches the patients who need it most promptly.

EVERSANA's President, Greg Skalicky, emphasized the importance of their operational model designed to navigate the complexities inherent in launching therapies aimed at rare diseases. He stated, "Our model is built to overcome the complexity of rare disease therapy launches." This assertion highlights the company’s commitment to not just facilitating the launch, but also ensuring that patients have swift access to breakthrough therapies such as PAPZIMEOS.

Accelerated Access for Patients

The deployment of EVERSANA's capabilities is set to occur immediately, focusing on accelerating patient access throughout the U.S. healthcare system. The robust strategies that will be employed are aimed at not only reaching healthcare providers but also educating them about the new therapy, thereby enhancing prescription rates and patient engagement.

As the landscape of the pharmaceutical industry evolves, the emphasis on patient experience remains at the forefront of EVERSANA's mission. By integrating patient feedback into all stages of product life cycles, they aim to craft solutions that are not only effective but also sustainable over the long term.

About EVERSANA

Founded with a vision to transform the life sciences sector, EVERSANA has positioned itself as a leading independent service provider, contributing to over 650 organizations, from nimble start-ups to established pharmaceutical enterprises. Their commitment spans the entirety of a product’s lifecycle, ensuring that both patients and healthcare professionals benefit from their innovations.

For those interested in learning more about the comprehensive commercialization services offered by EVERSANA, additional information is available on their website: eversana.com.

In conclusion, the partnership between EVERSANA and Precigen for the commercialization of PAPZIMEOS marks a notable advancement in the life sciences industry, emphasizing a shared dedication to improving patient outcomes and addressing the unique challenges associated with rare disease therapies. The future looks promising, with a robust strategy in place geared towards fulfilling unmet medical needs and providing hope for patients awaiting effective treatment options.